SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
Official title: SGLT-inhibitors in patients with hypertrophic cardiomyopathy
Funded at University of Pennsylvania · NIH-11412600 · Data updated 2026-11-12
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $671,727 |
| NIH project number | 5R33HL164376-04 |
| Project ID | NIH-11412600 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with symptomatic non-obstructive hypertrophic cardiomyopathy.
✕Less likely to help
Patients without non-obstructive HCM or those who cannot tolerate SGLT2 inhibitors may not benefit and could experience side effects.
What this research studies
People with non-obstructive hypertrophic cardiomyopathy often struggle with symptoms and heart complications, and there are limited proven treatments to improve their quality of life. This project will see if SGLT2 inhibitors, originally developed for diabetes, can be safely used in this heart condition and whether they show any signs of benefit. Researchers will assess safety, feasibility, and early hints of efficacy, exploring how the treatment affects heart energetics and function. The study will enroll adult participants with non-obstructive HCM at the University of Pennsylvania to gather data on tolerability and potential clinical signals.
Why it matters
Potential benefit: If successful, this approach could offer a new option to improve symptoms and possibly slow disease progression for people with non-obstructive HCM.
How similar studies have gone: SGLT2 inhibitors have shown cardioprotective effects in broader heart failure populations, but their use in non-obstructive HCM is being explored.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Day, Sharlene M — University of Pennsylvania
- Study coordinator: Day, Sharlene M
Related research
Other NIH-funded projects on the same topics.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
-
Boosting heart cell energy in hypertrophic cardiomyopathy
New approaches to improve mitochondrial energy in heart cells for people with hypertrophic cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.